291907
Female primary relationship partners and HIV risk among drug-using wswm of color
Methods: A pilot study of 90-minute in-depth interviews with drug-using WSWM of color (n=10) and participant-observation (N=35) was conducted in New York City in 2011.
Results: All women had experienced lifetime sexual victimization, 9/10 experienced childhood sexual abuse (CSA), with women who were involved in primary relationships with women (WPRW) experiencing the most extreme forms of CSA. Only WPRW engaged in transactional sex with men for drugs and/or money, and some partnered with men as a security blanket or front in order to pursue relationships with women on the down low. WPRW also tended to have sex with multiple male partners, drug-using men, and men who have sex with men and women. WPRW also provided specialized sexual services to men and were considered virginal and unused because of their gay status. IDU was only found among WPRW.
Conclusion: Female primary relationship partners may be indicative of a sexual minority status among WSWM that results in lower socio-economic status and higher HIV risk compared to women with male partners only.
Learning Areas:
Diversity and cultureOther professions or practice related to public health
Public health or related research
Social and behavioral sciences
Learning Objectives:
Explain why the gender of primary relationship partners may have impacted socio-economic status and how it was relevant to HIV risk.
Describe the different types of relationships that drug-using WSWM of color were involved in with women and men.
Discuss the eight high HIV risk behaviors that drug-using WSWM of color in primary relationships with women were more likely to engage in.
Keyword(s): Drug Use, Women's Sexuality
Qualified on the content I am responsible for because: I am the Principal Investigator and lead analyst of this study.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.